Table 1.
Clinical characteristics of patients with COVID-19
| Normal range | Median (IQR) | ||||
|---|---|---|---|---|---|
| All cases (n = 232) | Moderate cases (n = 102) | Severe cases (n = 130) | |||
| Survivors (n = 42) | Deaths (n = 88) | ||||
| Age (median, IQR, range, years)a,b | 68 (58–90), 20–88 | 65 (52–70), 20–87 | 67 (55–81), 35–88 | 75 (68–81), 47–86 | |
| Comorbidities | |||||
| Yesa | 133 (57.3%) | 36 (35.3%) | 29 (69.0%) | 68 (77.3%) | |
| Chronic pulmonary diseases | 8 (3.4%) | 1 (1.0%) | 2 (4.8%) | 5 (5.7%) | |
| Hypertension | 77 (33.2%) | 32 (31.4%) | 17 (40.5%) | 28 (31.8%) | |
| Diabetes | 25 (10.8%) | 8 (7.8%) | 5 (11.9%) | 12 (13.6%) | |
| Cardiovascular diseases | 25 (10.8%) | 9 (8.8%) | 6 (14.3%) | 10 (11.4%) | |
| Chronic liver diseases | 12 (5.2%) | 5 (4.9%) | 3 (7.1%) | 4 (4.5%) | |
| Chronic kidney diseases | 10 (4.3%) | 4 (3.9%) | 2 (4.8%) | 4 (4.5%) | |
| Malignant tumor | 6 (2.6%) | 2 (2.0%) | 1 (2.4%) | 3 (3.4%) | |
| Laboratory findings | |||||
| Leucocytes (× 109/L)a | 3.5–9.5 | 6.74 (4.82–8.91) | 5.40 (4.40–7.34) | 7.30 (5.72–9.99) | 8.06 (6.05–13.44) |
| Neutrophils (× 109/L)a | 1.8–6.3 | 4.53 (2.96–7.29) | 3.55 (2.63–4.78) | 5.47 (3.95–8.72) | 7.19 (4.66–11.85) |
| Lymphocytes (× 109/L)a | 1.1–3.2 | 0.98 (0.62–1.46) | 1.34 (0.95–1.74) | 0.82 (0.55–1.12) | 0.62 (0.47–0.95) |
| Hemoglobin (g/L) | 130–175 | 127 (117–138) | 126 (120–133) | 131 (116–141) | 132 (116–141) |
| Platelet (× 109/L)a,b | 125–350 | 214 (149–297) | 246 (194–337) | 215 (172–300) | 137 (103–214) |
| Total protein (g/L) | 64–83 | 68.2 (64.7–71.6) | 68.7 (65.4–71.7) | 68.5 (64.4–74.5) | 66.2 (63.5–70.7) |
| Albumin (g/L)a,b | 35–52 | 34.9 (31.4–40) | 39.1 (34.9–42.3) | 33.7 (31.6–37.5) | 31.2 (28.8–33.2) |
| Globulin (g/L)a | 20–35 | 32.4 (28.4–36.8) | 29.5 (26.5–33) | 35.7 (31.8–37.5) | 36.4 (32.8–40) |
| Lactate dehydrogenase (U/L)a,b | 135–225 | 262 (200–460) | 209 (171–265) | 310 (207–465) | 554 (370–808) |
| C-reactive protein (mg/L)a,b | < 1.0 | 19.1 (2.7–103.7) | 3.9 (0.7–13.4) | 19.9 (12.4–117.4) | 114.9 (64.4–147.7) |
| Procalcitonin (ng/mL)a | < 0.05 | 0.10 (0.05–0.21) | 0.06 (0.05–0.08) | 0.10 (0.08–0.35) | 0.28 (0.15–0.62) |
| D-dimer (ug/mL FEU)a,b | < 0.5 | 1.30 (0.33–4.64) | 0.38 (0.22–1.34) | 2.21 (1.16–4.59) | 5.38 (1.59–21) |
| Fibrinogen (g/L)a | 2–4 | 4.54 (3.39–5.75) | 3.85 (2.94–6.28) | 5.09 (4.55–6.28) | 5.14 (3.95–6.55) |
| Interleukin-6 (pg/mL)a,b | < 7 | 10.75 (1.80–30.49) | 2.64 (1.50–6.30) | 16.71 (10.75–28.71) | 63.54 (23.27–157.40) |
| Interleukin-2 receptor (U/mL)a | 223–710 | 644 (323–993) | 388 (259–557) | 821 (624–1506) | 1057 (717–1450) |
aStatistically significant index when comparing moderate cases with severe cases
bStatistically significant index when comparing survivors with deaths. P value < 0.05 is considered to be statistically significant